Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)

This study has been terminated.
(The study was stopped on november 2006 after inclusion was fulfilled)
Sponsor:
Information provided by:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT00316576
First received: April 19, 2006
Last updated: January 16, 2008
Last verified: January 2008
  Purpose

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.


Condition Intervention
Kidney Failure, Acute
Critical Illness
Procedure: Blood sampling for PCR

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients

Further study details as provided by University Hospital, Caen:

Primary Outcome Measures:
  • Incidence of ARF [ Time Frame: During ICU stay ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Mortality [ Time Frame: ICU and Hospital mortality ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 160
Study Start Date: May 2006
Study Completion Date: November 2006
Detailed Description:

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Consecutive patients admitted to ICU fore more than 48 hours

Criteria

Inclusion Criteria:

  • Age > 18 yrs
  • ICU stay > 48 hours

Exclusion Criteria:

  • Age < 18 yrs
  • Creatinine > 180 µmol/L
  • Absence of consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00316576

Locations
France
Medical Intensive care Unit; Caen University Hospital
Caen, France, 14000
Sponsors and Collaborators
University Hospital, Caen
Investigators
Principal Investigator: Damien du Cheyron, MD University Hospital, Caen
  More Information

No publications provided by University Hospital, Caen

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00316576     History of Changes
Other Study ID Numbers: 05-130
Study First Received: April 19, 2006
Last Updated: January 16, 2008
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Caen:
Kidney failure, Acute
Genetic Polymorphism
Angiotensin-converting enzyme

Additional relevant MeSH terms:
Critical Illness
Renal Insufficiency
Acute Kidney Injury
Disease Attributes
Pathologic Processes
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on September 16, 2014